Fulcrum Therapeutics
FULC
Fulcrum Therapeutics (FULC) news
Recent news
Fulcrum Therapeutics shares rise 3% after co to merge with Slate Medicines in all-stock deal
AInvest Wire · Aug 17, 2026Fulcrum Therapeutics, combined company cash expected to fund Slate's operations into 2029
AInvest Wire · Aug 17, 2026Fulcrum Therapeutics shares down 3.2% after the bell; filing shows co approves restructuring plan after discontinuing Pociredir for sickle cell disease
Fulcrum Therapeutics (Nasdaq: FULC) shares fell 3.2% in after-hours trading following the company’s announcement that it has discontinued its lead clinical program , pociredir, for the treatment of sickle cell disease (SCD) and has initiated a strategic review of its options. The decision comes…
AInvest Wire · Jun 4, 2026Fulcrum Therapeutics - workforce reduction communicated June 4, 2026; charges to be incurred in Q2 2026 - SEC filing
AInvest Wire · Jun 4, 2026Fulcrum Therapeutics - expects aggregate restructuring charges of about $4.2 mln - SEC filing
AInvest Wire · Jun 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.